Development of ON nanoconstructs for therapy |
|---|
| Host institution | Karolinska Institutet, Department of Biosciences and Nutrition, Huddinge (Stockholm), Sweden |
| Supervisor | Prof. Roger Strömberg |
| Co-Supervisors | Dr. Shalini Andersson, AstraZeneca, Sweden (Industrial) |
| Dr. Anders Dahlèn, AstraZeneca (Industrial) | |
| Prof. Florian Hollfelder, Cambridge University, UK (Academic) |
Project description
The project involves methodology development and synthesis of ON nanoconstructs for therapeutics; ONs conjugated to multiple entities for increased efficacy of ON therapy, including entities for increased tissue specificity and cell uptake, especially oligonucleotides therapy. The methodology work will also involve use and development of enzymes for synthesis of building blocks, in collaboration with Cambridge University. ON constructs for that affect the RNA levels (activation of transcription or translation), splice switching or RNA or strand invasion of DNA will be evaluated in collaboration with AstraZeneca, SOTON and SLL.
Secondments
This project is carried out in strong collaboration with the following groups:
Host laboratory
The group designs and makes bioactive molecules (and develops synthesis methods to achieve these) in order to provide tools for biomedical problems or to explore concepts for disease therapeutics. This includes work on artificial nucleases, modified and/or conjugated biomolecules (primarily peptides and oligonucleotides) as well as ligands for specific biopolymers. The group has all equipment and localities needed for the described project. This includes fully equipped organic synthesis and biopolymer synthesis laboratory including DNA/RNA synthesizer, Peptide/PNA synthesizer, UV-Vis, CD and Fluorescence spectrometers, HPLCs, NMR-spectrometer, ESI-TOF Mass spectrometer as well as access to modelling and simulation equipment as well as software and confocal microscopy.